A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Melanoma Clinical Trial

Official title:

A Single-Arm, Open-Label, Exploratory Study to Evaluate Safety and Efficacy of LM103 Injection in the Treatment of Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05366478
• Other study ID #: TIL-2021001
• Status: Recruiting
• Phase: Phase 1
• Start date: May 30, 2022
• Est. completion date: May 30, 2029

Study information

• Verified date: August 2022
• Source: Suzhou BlueHorse Therapeutics Co., Ltd.
• Contact: Xu Wen
• Phone: 13260921233
• Email: zhuce[@]lanmabio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.

Description:

This is an investigator initiated , single-arm, open-label ,exploratory study of LM103 Injection in patients with advanced solid tumors. Expanded TILs will be transferred to the patient after chemotherapy with cyclophosphamide and fludarabine. LM103 will be administered as a single dose on day 1. TIL transfer will be combined with IL-2 treatment. This study is planned to enroll 9-15 patients with advanced solid tumors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: May 30, 2029
• Est. primary completion date: May 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. AJCC (V8) stage III or IV melanoma, non-small cell lung cancer, cervical cancer and other solid tumors (confirmed by histology) for which existing treatment is ineffective or without standard treatment;

2. The patient has residual lesions that can be used for surgical resection (>1.5cm3) or biopsy (>1.5cm3) and measurable after resection for TIL collection and efficacy evaluation;

3. Laboratory inspection index requirements:

• Blood routine: lymphocyte ratio > 20%; neutrophil count > 1.0 × 10^9/L; white blood cells > 3.0 × 10^9/L; platelets > 100 × 10^9/L; hemoglobin > 80 g/ L;

• Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = upper limit of normal x 2.5, if there is liver metastasis = upper limit of normal x 5; alkaline phosphatase (ALP) = upper limit of normal x 2.5; total gallbladder Red pigment (TBIL)=normal upper limit×1.5;

• Renal function: urea = upper limit of normal × 1.5; creatinine (Cr) = upper limit of normal × 1.5;

4. Left ventricular ejection fraction (LVEF) = 50%;

5. ECOG physical condition is 0 or 1;

6. The expected survival time is more than 3 months;

Exclusion Criteria:

1. Suffering from active or previous autoimmune diseases ;

2. Severe liver and kidney dysfunction, severe heart disease, coagulation dysfunction, and hematopoietic dysfunction;

3. Combined with severe infection or persistent infection and cannot be effectively controlled;

4. Central nervous system metastasis and/or cancerous meningitis;

5. With uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage;

6. Requires systemic steroid therapy;

7. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HbcAb); positive for hepatitis C virus (HCV) antibody; positive for human immunodeficiency virus (HIV) antibody; positive for syphilis;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Cervical Carcinoma
• Melanoma
• Non Small Cell Lung Cancer

Intervention

Drug:
• Autologous tumor infiltrating lymphocytes (TILs)
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.

Locations

Country	Name	City	State
China	Tianjin Beichen Hospital	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Suzhou BlueHorse Therapeutics Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and severity of adverse events (AEs)	Adverse events are graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0	Up to 1 years
Secondary	Number of Participants With Objective Response	Participants displaying objective response associated with the treatment regimen per Response Evaluation Criteria in Solid Tumors (RECIST v.1.1). The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.	Up to 2 years
Secondary	Disease Control Rate (DCR)	Percentage of patients that meet CR, PR and SD criteria set in this study according to RECIST v1.1:	Up to 2 years
Secondary	Progression-Free Survival (PFS)	The time length between TIL infusion and confirmed subsequent disease progression according to RECIST 1.1	Up to 2 years
Secondary	The changes of the immunoreactivity during treatment	The changes from baseline of systemic immune Response markers: peripheral blood lymphocyte subtypes counts, cytokine, antigen-specific T-lymphocytes	Up to 2 years